Endo International PLC Company Profile (NASDAQ:ENDP)

Endo International PLC trades on the NASDAQ under the ticker symbol "ENDP."

Endo International PLC (NASDAQ:ENDP) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.13. The business earned $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The business's quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the company posted $1.08 earnings per share. View Endo International PLC's Earnings History.

Endo International PLC updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $3.45-3.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.61. The company issued revenue guidance of $3.45-3.60 billion, compared to the consensus revenue estimate of $3.54 billion.

19 brokerages have issued 1 year price objectives for Endo International PLC's shares. Their predictions range from $12.00 to $27.00. On average, they expect Endo International PLC's share price to reach $16.94 in the next year. View Analyst Ratings for Endo International PLC.

Here are some recent quotes from research analysts about Endo International PLC stock:

• 1. According to Zacks Investment Research, "2017 will continue to be challenging for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Shares of Endo have significantly underperformed the Medical-Drugs industry in the past one year. The company’s Generic segment is also under pressure given the challenging competitive landscape and pricing pressures. With the  company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Concerns relating to pricing are expected to remain a major overhang on the shares. However, Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables." (7/11/2017)
• 2. JMP Securities analysts commented, "The FDA panel voted 8 yes, 18 no, and 1 abstain on whether Opana ER's benefits outweigh the risk. The FDA was concerned that the new Opana ER formulation just shifts the abuse route from nasal to injections. We do not view Opana ER as a growth driver and it is only 4% of our 2017 revenue estimate while declining 13% y/y. Our $20 price target includes an equal blend of PEG ratio and EV/EBITDA analysis of 1.3x and 8.5x, respectively, on our 2017 estimates." (3/15/2017)
• 3. Royal Bank Of Canada analysts commented, "Yesterday's AdComs' vote of 18 to 8 (one abstain) on OPANA ER's benefits no longer outweighing its risks will push a decision on the product's fate back to FDA. Whether it is removed or sees added restrictions we think it is likely we will see some downward P&L pressure but it is also worth noting that the stock was -25% in Mar ahead of the anticipated panel." (3/15/2017)
• 4. Mizuho analysts commented, " We still like ENDP and its significant optionality, and we see upside to the stock for the following reasons: (1) Endo can likely sell Xiaflex for a healthy multiple with minimal EBITDA downside after cutting $30M in R&D expense for the planned cellulite trial and expenses tied to ~100 reps. (2) Endo may beat expectations following its conservative guide and/or longer than expected persistence of the Somar business, which is now also for sale. (3) Its high gross margin (55%) generic business with an attractive 117 ANDA pipeline, with 35 "first to files", is likely to attract consolidators in our view. (4) Its U.S.-based manufacturing plants contributed 95% of its production based on revenue, which may appeal to a potential buyer in the current political environment. We attribute remaining risk to a potential increase to the mesh liability accrual, but the company always has the option to litigate and delay. ENDP could therefore work in 2017 following an asset sale or takeover speculation. We reiterate our Buy rating and raise PT to $17 from $15 as we lower our WACC to 10% from 11% after mgmt. re-set expectations and the outlook." (3/3/2017)
• 5. Guggenheim analysts commented, "ENDP reported a 4Q16 beat and guided down for '17, which was expected given pricing pressure in generics. Lack of earnings visibility in '18 remains a concern. That said, we think patience will be rewarded and execution against its stated objectives will drive multiple expansion for ENDP's stock toward our $35 PT. Also, ENDP continues to be open to strategic alternatives if it cannot enhance shareholder value on its own. We think ENDP could simplify its business by selling its brand assets to pay down debt. In our view, ENDP is also an interesting generics asset (#4 player) in a consolidating industry." (2/28/2017)

Endo International PLC saw a drop in short interest during the month of June. As of June 30th, there was short interest totalling 20,084,394 shares, a drop of 11.0% from the June 15th total of 22,575,855 shares. Based on an average trading volume of 5,194,844 shares, the short-interest ratio is presently 3.9 days. Approximately 10.1% of the company's stock are short sold.

Some companies that are related to Endo International PLC include Icon Plc (ICLR), Mednax (MD), Masimo Corporation (MASI), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Taro Pharmaceutical Industries (TARO), Exact Sciences Corporation (EXAS), Medidata Solutions (MDSO), PAREXEL International Corporation (PRXL), Mallinckrodt PLC (MNK), Hikma Pharmaceuticals Plc (HKMPF), Acadia Healthcare Company (ACHC), Alere (ALR), Bio-Techne Corp (TECH), bluebird bio (BLUE), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART) and Neurocrine Biosciences (NBIX).

Endo International PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include First Quadrant L P CA (0.92%), American National Insurance Co. TX (0.06%), Oregon Public Employees Retirement Fund (0.03%), Meeder Asset Management Inc. (0.02%), Aperio Group LLC (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Endo International PLC stock include Arthur J Higgins, Matthew Joseph Maletta, Michael Hyatt, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Institutional Ownership Trends for Endo International PLC.

Endo International PLC's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Oregon Public Employees Retirement Fund and Aperio Group LLC. Company insiders that have sold Endo International PLC stock in the last year include Nancy J Hutson and Roger H Kimmel. View Insider Buying and Selling for Endo International PLC.

Endo International PLC's stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, James Investment Research Inc., Oakbrook Investments LLC, Capstone Asset Management Co. and Meeder Asset Management Inc.. Company insiders that have bought Endo International PLC stock in the last two years include Arthur J Higgins, Matthew Joseph Maletta, Paul Campanelli, Roger H Kimmel, Shane Cooke, Silva Rajiv De, Suketu Upadhyay, Susan Hall and William Spengler. View Insider Buying and Selling for Endo International PLC.

Shares of Endo International PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Endo International PLC stock can currently be purchased for approximately $12.32.